Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Priority to UY27321ApriorityCriticalpatent/UY27321A1/en
Publication of UY27321A1publicationCriticalpatent/UY27321A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende un inhibidor de lipasas, preferiblemente orlistat, con un punto de fusión - 37sC, un éster de ácido graso de sacarosa en donde el éster de ácido graso de sacarosa es un mono-, di-, tri-, o tetra-éster, y opcionalmente uno o más excipientes farmacéuticamente aceptables.The present invention relates to a pharmaceutical composition comprising a lipase inhibitor, preferably orlistat, with a melting point -37sC, a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di- , tri-, or tetra-ester, and optionally one or more pharmaceutically acceptable excipients.
UY27321A2002-06-052002-06-05
NEW PHARMACEUTICAL COMPOSITION
UY27321A1
(en)